Karla Kerlikowske

Karla Kerlikowske

Auto-generated profile, based on publicly available information

Karla Kerlikowske

Departments of Medicine and Epidemiology and Biostatistics, University of California, San Francisco, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 April 2010 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
KKKarla Kerlikowske
Karla Kerlikowske
AMAnnette M. Molinaro
Annette M. Molinaro
MGMona L. Gauthier
Mona L. Gauthier
HBHal K. Berman
Hal K. Berman
FWFred Waldman
Fred Waldman
TTThea D. Tlsty
Thea D. Tlsty
Studies have failed to identify characteristics of women who have been diagnosed with ductal carcinoma in situ (DCIS) and have a high or low risk of subsequent invasive cancer. We conducted a nested case–control study in a population-based cohort of 1162 women who were diagnosed with DCIS and treated by lumpectomy alone from 1983 to 1994. We collected clinical characteristics and information on subsequent tumors, defined as invasive breast cancer or DCIS diagnosed in the ipsilateral breast containing the initial DCIS lesion or at a regional or distant site greater than 6 months after initial treatment of DCIS (N = 324). We also conducted standardized pathology reviews and immunohistochemical staining for the estrogen receptor (ER), progesterone receptor, Ki67 antigen, p53, p16, epidermal growth factor receptor-2 (ERBB2, HER2/neu oncoprotein), and cyclooxygenase-2 (COX-2) on the initial paraffin-embedded DCIS tissue. Competing risk models were used to determine factors associated with risk of subsequent invasive cancer vs DCIS, and cumulative incidence survival functions were used to estimate 8-year risk. Factors associated with subsequent invasive cancer differed from those associated with subsequent DCIS. Eight-year risk of subsequent invasive cancer was statistically significantly (P = .018) higher for women with initial DCIS lesions that were detected by palpation or that were p16, COX-2, and Ki67 triple positive (p16+COX-2+Ki67+) (19.6%, 95% confidence interval [CI] = 18.0% to 21.3%) than for women with initial lesions that were detected by mammography and were p16, COX-2, and Ki67 triple negative (p16−COX-2−Ki67−) (4.1%, 95% CI = 3.4% to 5.0%). In a multivariable model, DCIS lesions that were p16+COX-2+Ki67+ or those detected by palpation were statistically significantly associated with subsequent invasive cancer, but nuclear grade was not. Eight-year risk of subsequent DCIS was highest for women with DCIS lesions that had disease-free margins of 1 mm or greater combined with either ER−ERBB2+Ki67+ or p16+COX-2−Ki67+ status (23.6%, 95% CI = 18.1% to 34.0%). Biomarkers can identify which women who were initially diagnosed with DCIS are at high or low risk of subsequent invasive cancer, whereas histopathology information cannot.

19 May 2015 in Annals of Internal Medicine
Verified
Journal Article
Closed access
KKKarla Kerlikowske
Karla Kerlikowske
WZWeiwei Zhu
Weiwei Zhu
ATAnna N.A. Tosteson
Anna N.A. Tosteson
BSBrian L. Sprague
Brian L. Sprague
JTJeffrey A. Tice
Jeffrey A. Tice
FCfor the Breast Cancer Surveillance Consortium*
for the Breast Cancer Surveillance Consortium*
High breast density increases breast cancer risk and can mask tumors, decreasing the sensitivity of mammography. This cohort study sought to better direct supplemental imaging discussions by determ... Background: Twenty-one states have laws requiring that women be notified if they have dense breasts and that they be advised to discuss supplemental imaging with their provider. Objective: To bette...

18 October 2011 in Annals of Internal Medicine
Verified
Journal Article
Closed access
KKKarla Kerlikowske
Karla Kerlikowske
RHRebecca A. Hubbard
Rebecca A. Hubbard
DMDiana L. Miglioretti
Diana L. Miglioretti
BGBerta M. Geller
Berta M. Geller
BYBonnie C. Yankaskas
Bonnie C. Yankaskas
FCfor the Breast Cancer Surveillance Consortium
for the Breast Cancer Surveillance Consortium
Few studies have examined the comparative effectiveness of digital versus film-screen mammography in U.S. community practice. In a large sample of women screened in community settings, digital and ... Background: Few studies have examined the comparative effectiveness of digital versus film-screen mammography in U.S. community practice. Objective: To determine whether the interpretive performanc...

6 March 2007 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
KKKarla Kerlikowske
Karla Kerlikowske
LILaura Ichikawa
Laura Ichikawa
DMDiana L. Miglioretti
Diana L. Miglioretti
DBDiana S. M. Buist
Diana S. M. Buist
PVPamela M. Vacek
Pamela M. Vacek
RBRachel Ballard-Barbash
Rachel Ballard-Barbash
Whether a change over time in clinically measured mammographic breast density influences breast cancer risk is unknown. From January 1993 to December 2003, data that included American College of Radiology Breast Imaging Reporting and Data System (BI-RADS) breast density categories (1–4 in order of increasing density) were collected prospectively on 301 955 women aged 30 and older who were not using postmenopausal hormone replacement therapy and underwent at least two screening mammography examinations; 2639 of the women were diagnosed with breast cancer within 1 year of the last examination. Women's first and last BI-RADS breast density (average 3.2 years apart) and logistic regression were used to model the odds of having invasive breast cancer or ductal carcinoma in situ diagnosed within 12 months of the last examination by change in BI-RADS category. Rates of breast cancer adjusted for age, mammography registry, and time between screening examinations were estimated from this model. All statistical tests were two-sided. The rate (breast cancers per 1000 women) of breast cancer was higher if BI-RADS breast density category increased from 1 to 2 (5.6, 95% confidence interval [CI] = 4.7 to 6.9) or 1 to 3 (9.9, 95% CI = 6.4 to 15.5) compared to when it remained at BI-RADS density of 1 (3.0, 95% CI = 2.3 to 3.9; P <.001 for trend). Similar and statistically significant trends between increased or decreased density and increased or decreased risk of breast cancer, respectively, were observed for women whose breast density category was initially 2 or 3 and changed categories. BI-RADS density of 4 on the first examination was associated with a high rate of breast cancer (range 9.1–13.4) that remained high even if breast density decreased. An increase in BI-RADS breast density category within 3 years may be associated with an increase in breast cancer risk and a decrease in density category with a decrease in risk compared to breast cancer risk in women in whom breast density category remains unchanged. Two longitudinal measures of BI-RADS breast density may better predict a woman's risk of breast cancer than a single measure.

1 October 2010 in JNCI Monographs
Verified
Journal Article
Open access
PDF file
KKKarla Kerlikowske
Karla Kerlikowske
Ductal carcinoma in situ (DCIS) is a relatively common diagnosis among women undergoing screening mammography. The greatest increases in DCIS incidence have been in non-comedo subtypes of DCIS that are not associated with subsequent invasive cancer. After a 500% increase in DCIS from 1983 to 2003, the incidence of DCIS declined in women aged 50 years and older, whereas the incidence in women younger than age 50 continues to increase. Having undergone mammography is one of the strongest and most prevalent risk factors associated with a diagnosis of DCIS. Other risk factors for DCIS are similar to that for invasive cancer including increasing age, family history of breast cancer, high mammographic breast density, and postmenopausal hormone therapy use. Treatment for DCIS is relatively aggressive with the use of both surgery and radiation therapy and most recently adjuvant hormonal therapy. Breast cancer mortality is low and similar with all types of treatment. New information regarding incidence of DCIS and subtypes of DCIS according to frequency of mammography and risk factors could lead to insights into the biology of DCIS.

20 August 2010 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
KKKarla Kerlikowske
Karla Kerlikowske
ACAndrea J. Cook
Andrea J. Cook
DBDiana S.M. Buist
Diana S.M. Buist
SCSteve R. Cummings
Steve R. Cummings
CVCeline Vachon
Celine Vachon
DMDiana L. Miglioretti
Diana L. Miglioretti
Purpose: We determined whether the association between breast density and breast cancer risk and cancer severity differs according to menopausal status and postmenopausal hormone therapy (HT) use.Methods: We collected data on 587,369 women who underwent 1,349,027 screening mammography examinations; 14,090 women were diagnosed with breast cancer. We calculated 5-year breast cancer risk from a survival model for subgroups of women classified by their Breast Imaging Reporting and Data System (BIRADS) breast density, age, menopausal status, and current HT use, assuming a body mass index of 25 kg/m2. Odds of advanced (ie, IIb, III, IV) versus early (ie, I, IIa) stage invasive cancer was calculated according to BIRADS density.Results: Breast cancer risk was low among women with low density (BIRADS-1): women age 55 to 59 years, 5-year risk was 0.8% (95% CI, 0.6 to 0.9%) for non-HT users and 0.9% (95% CI, 0.7% to 1.1%) for estrogen and estrogen plus progestin users. Breast cancer risk was high among women with very high density (BIRADS-4), particularly estrogen plus progestin users: women age 55 to 59 years, 5-year risk was 2.4% (95% CI, 2.0% to 2.8%) for non-HT users, 3.0% (95% CI, 2.6% to 3.5%) for estrogen users, and 4.2% (95% CI, 3.7% to 4.6%) for estrogen plus progestin users. Advanced-stage breast cancer risk was increased 1.7-fold for postmenopausal HT users who had very high density (BIRADS-4) compared to those with average density (BIRADS-2).Conclusion: Postmenopausal women with high breast density are at increased risk of breast cancer and should be aware of the added risk of taking HT, especially estrogen plus progestin.